PAXIL

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
PAXIL
Generic name
PAROXETINE HYDROCHLORIDE
Manufacturer
Apotex Corp
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e
SPL ID
e1aa474e-4ffe-6c6c-8037-84907819bb88
Version
13
Effective date
2026-09-29
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:07
Harmonized routes table
Harmonized routes
ORAL

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . PAXIL is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning . Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) PAXIL is not approved for use in pediatric patients ( 5.1 , 8.4 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 2 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Serotonin Syndrome: : Monitor all patients taking PAXIL for the emergence of serotonin syndrome. . If occurs, immediately discontinue PAXIL and serotonergic agents and initiate supportive measures. ( 5.2 ) Embryofetal Toxicity: For women who intend to become pregnant or who are in their first trimester of pregnancy, PAXIL, should be initiated only after consideration of the other available treatment options ( 5.4 , 8.1 ) Increased Risk of Bleeding: For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL ( 5.5 ) Seizures: Use with caution in patients with seizure disorders. Discontinue PAXIL in any patient who develop a seizure ( 5.8 ) Angle-Closure Glaucoma: Avoid use of PAXIL in patients with untreated anatomically narrow angles. ( 5.9 ) Hyponatremia: In patients with symptomatic hyponatremia, discontinue PAXIL and institute appropriate medical intervention ( 5.10 ) Sexual Dysfunction: Inquire about sexual function prior to initiation of PAXIL and to inquire specifically about changes in sexual function during PAXIL treatment ( 5.11 ) 5.1 Suicidal Thoughts and Behaviors in Pediatric Patients and Young Adults In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There were differences in absolute risk of suicidal thoughts and behaviors across the different uses, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2. Table 2: Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric 1 and Adult Patients Age Range Drug-Placebo Difference in Number of Patients with Suicidal Thoughts and Behaviors per 1,000 Patients Treated Increases Compared to Placebo <18 years old 14 additional cases 18-24 years old 5 additional cases Decreases Compared to Placebo 25-64 years old 1 fewer case ≥65 years old 6 fewer cases 1 PAXIL is not approved for use in pediatric patients. It is unknown whether the risk of suicidal thoughts and behaviors in pediatric patients and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing PAXIL, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors. 5.2 Serotonin Syndrome Selective serotonin reuptake inhibitors (SSRIs), including PAXIL, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications ( 4 ), Drug Interactions ( 7.1 )]. Serotonin syndrome can also occur when PAXIL is used alone. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The concomitant use of PAXIL with MAOIs is contraindicated. In addition, do not initiate PAXIL in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes of administration (such as orally or local tissue injection) or at lower doses. If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking PAXIL discontinue PAXIL before initiating treatment with the MAOI [see Contraindications ( 4 ) and Drug Interactions ( 7 )]. Monitor all patients taking PAXIL for the emergence of serotonin syndrome. Discontinue treatment with PAXIL and any concomitant serotonergic drug immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of PAXIL with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. 5.3 Drug Interactions Leading to QTc Interval Prolongation Cases of QTc interval prolongation have been reported with the use of paroxetine, although causal relationship with PAXIL has not been established. PAXIL is a strong CYP2D6 inhibitor. Concomitant use of PAXIL with CYP2D6 substrates that prolong the QTc interval can increase the concentration of those CYP2D6 substrates and may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsade de pointes, other serious arrythmias, and sudden death. The concomitant use of PAXIL is contraindicated with CYP2D6 substrates that prolong the QTc interval [see Drug Interactions ( 7 ) and Clinical Pharmacology ( 12.3 )]. 5.4 Embryofetal Toxicity PAXIL can cause fetal harm when administered to a pregnant woman. Based on meta-analyses of epidemiological studies, exposure to paroxetine in the first trimester of pregnancy is associated with a less than 2-fold increase in the rate of cardiovascular malformations among infants. For women who intend to become pregnant or who are in their first trimester of pregnancy, PAXIL, should be initiated only after consideration of the other available treatment options [see Use in Specific Populations ( 8.1 )]. 5.5 Increased Risk of Bleeding Drugs that interfere with serotonin reuptake inhibition, including PAXIL, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Use in Specific Populations ( 8.1 )]. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the increased risk of bleeding associated with the concomitant use of PAXIL and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing PAXIL. 5.6 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with PAXIL or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of PAXIL for unipolar depression, hypomania or mania occurred in approximately 1% of PAXIL-treated patients compared to 1.1% of active-control and 0.3% of placebo-treated patients. Prior to initiating treatment with PAXIL, screen patients for any personal or family history of bipolar disorder, mania, or hypomania. 5.7 Discontinuation Syndrome Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. During clinical trials of GAD and PTSD, gradual decreases in the daily PAXIL dosage by 10 mg/day at weekly intervals followed by 1 week at 20 mg/day was used before treatment was discontinued. The following adverse reactions were reported at an incidence of 2% or greater for PAXIL and were at least twice that reported for placebo: abnormal dreams, paresthesia, and dizziness adverse reactions have been reported upon discontinuation of treatment with PAXIL in pediatric patients. The safety and effectiveness of PAXIL in pediatric patients have not been established [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )]. When discontinuing PAXIL, a gradual reduction in dosage rather than abrupt cessation is recommended whenever possible [see Dosage and Administration ( 2.7 )] . 5.8 Seizures PAXIL has not been systematically evaluated in patients with seizure disorders. Patients with history of seizures were excluded from clinical studies. During clinical studies, seizures occurred in 0.1% of patients treated with PAXIL. PAXIL should be prescribed with caution in patients with a seizure disorder. Discontinue PAXIL in any patient who develops a seizure. 5.9 Angle-Closure Glaucoma The pupillary dilation that occurs following use of many antidepressant drugs including PAXIL may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Cases of angle-closure glaucoma associated with use of PAXIL have been reported. Avoid use of antidepressants, including PAXIL in patients with untreated anatomically narrow angles. 5.10 Hyponatremia Hyponatremia may occur as a result of treatment with SSRIs, including PAXIL. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute hyponatremia cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )]. In patients with symptomatic hyponatremia, discontinue PAXIL and institute appropriate medical intervention. 5.11 Sexual Dysfunction Use of SSRIs, including PAXIL, may cause symptoms of sexual dysfunction [see Adverse Reactions ( 6.1 )] . In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm. Recommend prescribers inquire about sexual function prior to initiation of PAXIL and to inquire specifically about changes in sexual function during PAXIL treatment because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtain a detailed history (including timing of symptom onset) because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment for sexual dysfunction. 5.12 Risk of Reduced of Efficacy of Tamoxifen Some studies have shown that the efficacy of tamoxifen, as measured by breast cancer relapse and mortality, may be reduced with concomitant use of PAXIL as a result of paroxetine’s irreversible CYP2D6 inhibition and lower concentration of the active metabolite of tamoxifen [see Drug Interactions ( 7 )]. One study suggested that the risk may increase with longer duration of concomitant use of PAXIL and tamoxifen. However, other studies have failed to demonstrate such a risk. When tamoxifen is used for the treatment or prevention of breast cancer, prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition rather than PAXIL. 5.13 Fracture Risk Epidemiological studies on fracture risk during exposure to some antidepressant drugs, including SSRIs, have reported an association between antidepressant drug treatment and fractures. There are multiple possible causes for this association, and it is unknown to what extent fracture risk is directly attributable to SSRI treatment.

warnings and cautions table

<table frame="box" rules="all"> <tbody> <tr> <th>Age Range</th> <th> <content styleCode="bold">Drug-Placebo Difference in Number of Patients with Suicidal Thoughts and Behaviors per 1,000 Patients Treated</content> </th> </tr> <tr> <td/> <td align="center"> <content styleCode="bold">Increases Compared to Placebo</content> </td> </tr> <tr> <td align="center">&lt;18 years old</td> <td align="center">14 additional cases</td> </tr> <tr> <td align="center">18-24 years old</td> <td align="center">5 additional cases</td> </tr> <tr> <td align="center"/> <td align="center"> <content styleCode="bold">Decreases Compared to Placebo</content> </td> </tr> <tr> <td align="center">25-64 years old</td> <td align="center">1 fewer case</td> </tr> <tr> <td align="center">&#x2265;65 years old</td> <td align="center">6 fewer cases</td> </tr> </tbody> </table>

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 7 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are included in more detail in other sections of the prescribing information: Suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] Serotonin syndrome [see Warnings and Precautions ( 5.2 )] Increased risk of bleeding [see Warnings and Precautions ( 5.5 )] Activation of mania/hypomania [see Warnings and Precautions ( 5.6 )] Discontinuation syndrome [see Warnings and Precautions ( 5.7 )] Seizures [see Warnings and Precautions ( 5.8 )] Angle-closure glaucoma [see Warnings and Precautions ( 5.9 )] Hyponatremia [see Warnings and Precautions ( 5.10 )] Sexual Dysfunction [see Warnings and Precautions ( 5.11 )] Fracture [see Warnings and Precautions ( 5.12 )] Most common adverse reactions (≥5% and at least twice placebo) are abnormal ejaculation, , asthenia, constipation, decreased appetite, diarrhea, dizziness, dry mouth, female genital disorder, impotence, infection, insomnia, libido decreased, male genital disorder, nausea, nervousness, somnolence, sweating, tremor, yawn. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data for PAXIL are from: 6 six‑week clinical trials in adult patients with MDD. Patients in the PAXIL group received PAXIL 20 mg to 50 mg once daily (Studies MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6) [see Clinical Studies ( 14.1 )]. 2 twelve-week clinical trials in adult patients with OCD. Patients in the PAXIL group received PAXIL 20 mg to 60 mg once daily (Studies OCD-1 and OCD-2) [see Clinical Studies ( 14.2 )]. 3 ten to twelve‑week clinical trials in adult patients with PD. Patients in the PAXIL group received PAXIL 10 mg to 60 mg once daily (Studies PD-1, PD-2, and PD-3) [see Clinical Studies ( 14.3 )]. 3 twelve-week clinical trials in adult patients with SAD. Patients in the PAXIL group received PAXIL 20 mg to 50 mg once daily (Studies SAD-1, SAD-2, and SAD-3) [see Clinical Studies ( 14.4 )]. 3 eight‑week clinical trials in adult patients with GAD. Patients in the PAXIL group received PAXIL 10 mg to 50 mg once daily (Studies GAD-1, GAD-2, and GAD-3) [see Clinical Studies ( 14.5 )] . 2 twelve‑week clinical trials in adult patients with PTSD. Patients in the PAXIL group received PAXIL 20 mg to 50 mg once daily (Studies PTSD -1 and PTSD -2) [see Clinical Studies ( 14.6 )] . Adverse Reactions Leading to Discontinuation In clinical studies in adults with MDD, SAD, OCD, PD, GAD, and PTSD, 20% (1,199/6,145), 16% (84/522), 12% (64/542), 9% (44/469), 11% (79/735), and 12% (79/676) of PAXIL-treated patients, respectively, discontinued treatment due to an adverse reaction. The most common adverse reactions (³1%) associated with discontinuation (i.e., those adverse reactions associated with dropout at a rate approximately twice or greater for the PAXIL group compared to the placebo group) are presented in Table 3. Table 3: Adverse Reactions That Led to Discontinuation (≥1% of PAXIL-Treated Patients and Greater than Placebo) in MDD, OCD, PD, SAD, GAD, and PTSD Adult Studies MDD OCD PD SAD GAD PTSD PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo PAXIL Placebo CNS Adverse Reactions Somnolence 2.3% 0.7% --- 1.9% 0.3% 3.4% 0.3% 2% 0.2% 2.8% 0.6% Insomnia --- --- 1.7% 0% 1.3% 0.3% 3.1% 0% --- --- Agitation 1.1% 0.5% --- --- --- Tremor 1.1% 0.3% --- 1.7% 0% 1% 0.2% Anxiety --- --- --- 1.1% 0% --- --- Dizziness --- --- 1.5% 0% 1.9% 0% 1% 0.2% --- --- Gastrointestinal Adverse Reactions Constipation --- 1.1% 0% --- --- Nausea 3.2% 1.1% 1.9% 0% 3.2% 1.2% 4% 0.3% 2% 0.2% 2.2% 0.6% Diarrhea 1% 0.3% --- Dry mouth 1% 0.3% --- --- --- Vomiting 1% 0.3% --- 1% 0% --- --- Flatulence 1% 0.3% --- --- Other Adverse Reactions Asthenia 1.6% 0.4% 1.9% 0.4% 2.5% 0.6% 1.8% 0.2% 1.6% 0.2% Abnormal Ejaculation a 1.6% 0% 2.1% 0% 4.9% 0.6% 2.5% 0.5% --- --- Sweating 1% 0.3% --- 1.1% 0% 1.1% 0.2% --- --- Impotence a --- 1.5% 0% --- --- Libido Decreased 1% 0% --- --- If numbers are not provided in the table, the incidence of the adverse reactions in PAXIL-treated patients was not >1% or was not ≥ 2 times the incidence in placebo-treated patients . a. Incidence corrected for sex. Most Common Adverse Reactions The most commonly observed adverse reactions associated with the use of PAXIL (incidence of 5% or greater and at least twice that for placebo) were: MDD: Asthenia, sweating, nausea, decreased appetite, somnolence, dizziness, insomnia, tremor, nervousness, ejaculatory disturbance, and other male genital disorders. OCD: Nausea, dry mouth, decreased appetite, constipation, dizziness, somnolence, tremor, sweating, impotence, and abnormal ejaculation. PD: Asthenia, sweating, decreased appetite, libido decreased, tremor, abnormal ejaculation, female genital disorders, and impotence. SAD: Sweating, nausea, dry mouth, constipation, decreased appetite, somnolence, tremor, libido decreased, yawn, abnormal ejaculation, female genital disorders, and impotence. GAD: Asthenia, infection, constipation, decreased appetite, dry mouth, nausea, libido decreased, somnolence, tremor, sweating, and abnormal ejaculation. PTSD: Asthenia, sweating, nausea, dry mouth, diarrhea, decreased appetite, somnolence, libido decreased, abnormal ejaculation, female genital disorders, and impotence. Adverse Reactions in Adult Patients with MDD Table 4 presents the adverse reactions that occurred at an incidence of 1% or more and greater in the PAXIL group than the placebo group in clinical trials in adult patients with MDD (Studies MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6 ). Table 4: Adverse Reactions (≥1% of PAXIL-Treated Patients and Greater than Placebo Treated Patients ) in 6-Week Clinical Trials od Adults with MDD PAXIL (n = 421) Placebo (n = 421) Nausea 26% 9% Somnolence 23% 9% Dry Mouth 18% 12% Headache 18% 17% Asthenia 15% 6% Constipation 14% 9% Ejaculatory Disyurbance a 13% 0% Dizziness 13% 6% Insomnia 13% 6% Diarrhea 12% 8% Sweating 11% 2% Other Male Genital Disorders b 10% 0% Tremor 8% 2% Decreased Appetite 6% 2% Nervousness 5% 3% Anxiety 5% 3% Yawn 4% 0% Blurred Vision 4% 1% Flatulence 4% 2% Paresthesia 4% 2% Palpitation 3% 1% Vasodilation 3% 1% Libido Decreased 3% 0% Urination Disorder d 3% 0% Urinary Frequency 3% 1% Taste Perversion 2% 0% Female Genital Disorders d 2% 0% Oropharynx Disorder e 2% 0% Myopathy 2% 1% Dyspepsia 2% 1% Rash 2% 1% Drugged Feeling 2% 1% Myalgia 2% 1% Confusion 1% 0% Myasthenia 1% 0% a. Ejaculatory disturbance mostly “ejaculatory delay.” b. Other male genital disorders percentage corrected for sex. Includes “anorgasmia,” “erectile difficulties,” “delayed ejaculation/orgasm,” and “sexual dysfunction,” and “impotence.” c. Urination Disorder Includes mostly “difficulty with micturition” and “urinary hesitancy.” d. Female Genital Disorders includes mostly “anorgasmia” and “difficulty reaching climax/orgasm.” e.Oropharynx disorder includes mostly “lump in throat” and “tightness in throat.” Dose dependent adverse reactions in fixed‑dose studies (Study MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6) for the treatment of adults with MDD that compared PAXIL10 mg, 20 mg, 30 mg, and 40 mg once daily with placebo once daily are shown in Table 5. Table 5. Adverse Reactions (≥5% of PAXIL-Treated Patients and ≥ Twice the Rate of Placebo-Treated Patients) in a Study of Adults with MDD (Study MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6) Placebo (n = 51) PAXIL 10 mg/day (n=102) 20 mg/day (n=104) 30 mg/day (n=101) 40 mg/day (n=102) Nausea 14% 15% 27% 35% 36% Somnolence 8% 13% 18% 21% 22% Dry Mouth 2% 11% 18% 16% 21% Diarrhea 8% 10% 19% 8% 15% Tremor 8% 0% 8% 8% 15% Asthenia 0% 3% 11% 14% 13% Abnormal Ejaculation 0% 6% 7% 11% 13% Constipation 6% 5% 8% 10% 13% Dizziness 4% 7% 8% 9% 13% Sweating 2% 1% 7% 9% 12% Blurred Vision 2% 3% 3% 2% 8% Anxiety 0% 2% 6% 6% 6% Paresthesia 0% 3% 1% 5% 6% Decreased Appetite 2% 2% 6% 4% 5% Male Genital Disorders 0% 4% 9% 6% 4% Nervousness 0% 6% 6% 4% 3% Impotence 0% 2% 4% 6% 2% Adverse Reactions in Adult Patients with OCD, PD, and SAD Table 6 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials in adult patients with OCD, PD, and SAD (i.e., Studies OCD-1, OCD-2, PD-1, PD-2, PD-3, SAD-1, SAD-2, and SAD-3). Dose -related adverse reactions in a 10-week fixed-dose study (Study PD-1) that compared placebo and PAXIL 10 mg, 20 mg, and 40 mg once daily in the treatment of adults with PD were asthenia, dry mouth, anxiety, libido decreased, tremor, and abnormal ejaculation. There was no clear relationship between adverse reactions and the PAXIL dosage in a: Fixed dose study (Study OCD-1) that compared placebo and PAXIL 20 mg, 40 mg, and 60 mg once daily in the treatment of adults with OCD Fixed dose study (SAD-3) that compared placebo and PAXIL 20 mg, 40 mg and 60 mg once daily in the treatment of adults with SAD. Table 6. Adverse Reactions (≥2% of PAXIL-Treated Patients and Greater than Placebo- Treated Patients) in 10 to 12-Week Clinical Trials for OCD, PD, and SAD OCD PD SAD PAXIL (n = 542) Placebo (n = 265) PAXIL (n = 469) Placebo (n = 324) PAXIL (n = 425) Placebo (n = 339) Somnolence 24% 7% 19% 11% 22% 5% Insomnia 24% 13% 18% 10% 21% 16% Abnormal Ejaculation a 23% 1% 21% 1% 28% 1% Nausea 23% 10% 23% 17% 25% 7% Asthenia 22% 14% 14% 5% 22% 14% Dry Mouth 18% 9% 18% 11% 9% 3% Constipation 16% 6% 8% 5% 5% 2% Dizziness 12% 6% 14% 10% 11% 7% Tremor 11% 1% 9% 1% 9% 1% Diarrhea 10% 10% 12% 7% 9% 3% Sweating 9% 3% 14% 6% 9% 2% Decreased Appetite 9% 3% 7% 3% 8% 2% Nervousness 9% 8% --- --- 8% 7% Impotence a 8% 1% 5% 0% 5% 1% Decreased libido 7% 4% 9% 1% 12% 1% Abnormal Dreams 4% 1% --- --- --- --- Vasodilation 4% 1% ---- --- --- --- Abnormal Vision 4% 2% --- --- 4% 1% Increased Appetite 4% 3% 2% 1% 2% 1% Female Genital Disorder a 3% 0% 9% 1% 9% 1% Myoclonus 3% 0% 3% 2% 2% 1% Depersonalization 3% 0% --- --- --- --- Urination Impaired 3% 0% --- --- --- --- Concentration Impaired 3% 2% --- --- 4% 1% Chest Pain 3% 2% - - - - Rash 3% 2% --- --- --- --- Urinary Frequency 3% 1% 2% 0% --- --- Palpitation 2% 0% --- --- --- --- Taste Perversion 2% 0% --- --- --- --- Chills 2% 1% 2% 1% --- --- Urinary Tract Infection 2% 1% 2% 1% --- --- Amnesia 2% 1% - - - - Back Pain - - 3% 2% - - Agitation --- --- 5% 4% 3% 1% Anxiety --- --- 5% 4% 5% 4% Abdominal Pain - - 4% 3% --- --- Rhinitis - - 3% 0% - - Yawn - - - - 5% 1% Dysmenorrhea --- --- --- --- 5% 4% Dyspepsia - - - - 4% 2% Pharyngitis --- --- --- --- 4% 2% Myalgia --- --- --- --- 4% 3% Trauma --- --- --- --- 3% 1% Flatulence - - - - - 2% Vomiting - - - - 1% a. Percentage corrected for sex. Adverse Reactions in Adult Patients with GAD and PTSD Table 7 presents adverse reactions that occurred at a frequency of 2% or more in clinical trials in adult patients with GAD and PTSD (i.e., Studies GAD-1, GAD-2, PTSD-1, and PTSD-2). Dose-related adverse reactions in a fixed dose studies that compared: Placebo and PAXIL 20 mg and 40 mg once daily in the treatment of adults with GAD were asthenia, constipation, and abnormal ejaculation. Placebo and PAXIL 20 mg and 40 mg once daily in the treatment of adults with PTSD were impotence and abnormal ejaculation. Table 7. Adverse Reactions (≥2% of PAXIL-Treated Patients and Greater than Placebo) in 8- to 12-Week Clinical Trials for GAD and PTSD a Generalized Anxiety Disorder Posttraumatic Stress Disorder Paxil (n= 735) Placebo (n = 529) PAXIL (n = 676) Placebo (n = 504) Abnormal Ejaculation a 25% 2% 13% 2% Nausea 20% 5% 19% 8% Headache 17% 14% --- --- Somnolence 15% 5% 16% 5% Asthenia 14% 6% 12% 4% Dry Mouth 11% 5% 10% 5% Insomnia 9% 2% 5% 2% Constipation 10% 2% 5% 3% Libido Decreased 9% 2% 5% 3% Diarrhea 9% 7% 11% 5% Respiratory Disorder 7% 5% --- --- Sweating 6% 2% 5% 1% Infection 6% 3% 5% 4% Dizziness 6% 5% 6% 5% Decreased Appetite 5% 1% 6% 3% Tremor 5% 1% 4% 1% Female Genital Disorder a 4% 1% 5% 1% Yawn 4% --- 2% <1% Nervousness 4% 3% --- --- Sinusitis 4% 3% --- --- Impotence a 4% 3% 9% 1% Vasodilation 3% 1% 2% 1% Vomiting 3% 2% 3% 2% Abnormal Vision 2% 1% 3% 1% Trauma 6% 5% Dyspepsia --- --- 5% 3% Abdominal Pain 4% 3% Abnormal Dreams 3% a. Percentage corrected for sex Male and Female Sexual Dysfunction The percentage of patients who reported symptoms of sexual dysfunction in males and females with MDD, OCD, PD, SAD, GAD, and PTSD (i.e., Studies MDD-1, MDD-2, MDD-3, MDD-4, MDD-5, and MDD-6; OCD-1 and OCD-2; PD-1, PD-2, and PD-3; SAD-1, SAD-2, and SAD-3; GAD-1 and GAD-2; PTSD-1 and PTSD-2) are displayed in Table 8. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and healthcare providers may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in labeling may underestimate their actual incidence. PAXIL treatment has been associated with several cases of priapism. In those cases, with a known outcome, patients recovered without sequelae. Table 8. Adverse Reactions Related to Sexual Dysfunction in Clinical Trials of Adults with MDD, OCD, PD, SAD, GAD, and PTSD Males PAXIL (n=1446) Placebo (n=1042) Decreased Libido 6% to 15% 0% to 5% Ejaculatory Disturbance 13% to 28% 0% to 2% Impotence 2% to 9% 0% to 3% Females PAXIL (n=1,822) Placebo (n=1,340) Decreased Libido 0% to 9% 0% to 2% Orgasmic Disturbance 2% to 9% 0% to 1% Hallucinations In pooled clinical trials of PAXIL, hallucinations were observed in 0.2% of PAXIL-treated patients compared to 0.1% of placebo-treated patients . Less Common Adverse Reactions The following adverse reactions occurred during the clinical studies of PAXIL and are not included elsewhere in the labeling. Adverse reactions are categorized by body system and listed in order of decreasing frequency according to the following definitions: Frequent adverse reactions are those that occurred on 1 or more occasion in at least 1/100 patients. Infrequent adverse reactions are those that occurred in 1/100 to 1/1,000 patients Rare adverse reactions are those that occurred in fewer than 1/1,000 patients. Body as a Whole Infrequent: Allergic reaction, chills, face edema, malaise, neck pain; rare: Adrenergic syndrome, cellulitis, moniliasis, neck rigidity, pelvic pain, peritonitis, sepsis, ulcer. Cardiovascular System Frequent: Hypertension, tachycardia; infrequent: Bradycardia, hematoma, hypotension, migraine, postural hypotension, syncope; rare: Angina pectoris, arrhythmia nodal, atrial fibrillation, bundle branch block, cerebral ischemia, cerebrovascular accident, congestive heart failure, heart block, low cardiac output, myocardial infarct, myocardial ischemia, pallor, phlebitis, pulmonary embolus, supraventricular extrasystoles, thrombophlebitis, thrombosis, varicose vein, vascular headache, ventricular extrasystoles. Digestive System Infrequent: Bruxism, colitis, dysphagia, eructation, gastritis, gastroenteritis, gingivitis, glossitis, increased salivation, abnormal liver function tests, rectal hemorrhage, ulcerative stomatitis; rare: Aphthous stomatitis, bloody diarrhea, bulimia, cardiospasm, cholelithiasis, duodenitis, enteritis, esophagitis, fecal impactions, fecal incontinence, gum hemorrhage, hematemesis, hepatitis, ileitis, ileus, intestinal obstruction, jaundice, melena, mouth ulceration, peptic ulcer, salivary gland enlargement, sialadenitis, stomach ulcer, stomatitis, tongue discoloration, tongue edema, tooth caries. Endocrine System Rare: Diabetes mellitus, goiter, hyperthyroidism, hypothyroidism, thyroiditis. Hemic and Lymphatic Systems Infrequent: Anemia, leukopenia, lymphadenopathy, purpura; rare: Abnormal erythrocytes, basophilia, bleeding time increased, eosinophilia, hypochromic anemia, iron deficiency anemia, leukocytosis, lymphedema, abnormal lymphocytes, lymphocytosis, microcytic anemia, monocytosis, normocytic anemia, thrombocythemia, thrombocytopenia. Metabolic and Nutritional Frequent: Weight gain; infrequent: Edema, peripheral edema, SGOT increased, SGPT increased, thirst, weight loss; rare: Alkaline phosphatase increased, bilirubinemia, BUN increased, creatinine phosphokinase increased, dehydration, gamma globulins increased, gout, hypercalcemia, hypercholesteremia, hyperglycemia, hyperkalemia, hyperphosphatemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, ketosis, lactic dehydrogenase increased, non‑protein nitrogen (NPN) increased. Musculoskeletal System Frequent: Arthralgia; infrequent: Arthritis, arthrosis; rare: Bursitis, myositis, osteoporosis, generalized spasm, tenosynovitis, tetany. Nervous System Frequent: Emotional lability, vertigo; infrequent: Abnormal thinking, alcohol abuse, ataxia, dystonia, dyskinesia, euphoria, hostility, hypertonia, hypesthesia, hypokinesia, incoordination, lack of emotion, libido increased, manic reaction, neurosis, paralysis, paranoid reaction; rare: Abnormal gait, akinesia, antisocial reaction, aphasia, choreoathetosis, circumoral paresthesias, convulsion, delirium, delusions, diplopia, drug dependence, dysarthria, extrapyramidal syndrome, fasciculations, grand mal convulsion, hyperalgesia, hysteria, manic-depressive reaction, meningitis, myelitis, neuralgia, neuropathy, nystagmus, peripheral neuritis, psychotic depression, psychosis, reflexes decreased, reflexes increased, stupor, torticollis, trismus, withdrawal syndrome. Respiratory System Infrequent: Asthma, bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu; rare: Emphysema, hemoptysis, hiccups, lung fibrosis, pulmonary edema, sputum increased, stridor, voice alteration. Skin and Appendages Frequent: Pruritus; infrequent: Acne, alopecia, contact dermatitis, dry skin, ecchymosis, eczema, herpes simplex, photosensitivity, urticaria; rare: Angioedema, erythema nodosum, erythema multiforme, exfoliative dermatitis, fungal dermatitis, furunculosis; herpes zoster, hirsutism, maculopapular rash, seborrhea, skin discoloration, skin hypertrophy, skin ulcer, sweating decreased, vesiculobullous rash. Special Senses Frequent: Tinnitus; infrequent: Abnormality of accommodation, conjunctivitis, ear pain, eye pain, keratoconjunctivitis, mydriasis, otitis media; rare: Amblyopia, anisocoria, blepharitis, cataract, conjunctival edema, corneal ulcer, deafness, exophthalmos, eye hemorrhage, glaucoma, hyperacusis, night blindness, otitis externa, parosmia, photophobia, ptosis, retinal hemorrhage, taste loss, visual field defect. Urogenital System Infrequent: Amenorrhea, breast pain, cystitis, dysuria, hematuria, menorrhagia, nocturia, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginitis; rare: Abortion, breast atrophy, breast enlargement, endometrial disorder, epididymitis, female lactation, fibrocystic breast, kidney calculus, kidney pain, leukorrhea, mastitis, metrorrhagia, nephritis, oliguria, salpingitis, urethritis, urinary casts, uterine spasm, urolith, vaginal hemorrhage, vaginal moniliasis. 6.2 Postmarketing Experience The following reactions have been identified during post approval use of paroxetine. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood system disorders : events related to impaired hematopoiesis (including agranulocytosis, aplastic anemia, bone marrow aplasia and pancytopenia), hemolytic anemia Cardiac disorders : torsade de pointes, ventricular fibrillation, ventricular tachycardia Endocrine disorders : hyperprolactinemia, syndrome of inappropriate antidiuretic hormone (SIADH) secretion Gastrointestinal disorders : acute pancreatitis Hepatobiliary disorders : elevated liver function tests (the most severe cases were deaths due to liver necrosis, and grossly elevated transaminases associated with severe liver dysfunction) Immune system disorders : anaphylactic reaction, vasculitis syndromes (such as Henoch-Schönlein purpura). Metabolism and nutrition disorders : porphyria Musculoskeletal and connective tissue disorders: Hypertonia Nervous system disorders : extrapyramidal symptoms (i.e. akathisia, bradykinesia, cogwheel rigidity, oculogyric crisis which has been associated with concomitant use of pimozide), Guillain-Barré Syndrome, anosmia, hyposmia, optic neuritis, restless legs syndrome (RLS), status epilepticus Pregnancy, puerperium and perinatal conditions : eclampsia, premature birth Renal disorders : acute renal failure Reproductive system and breast disorders : galactorrhea, priapism Respiratory, disorders : allergic alveolitis, laryngospasm, pulmonary hypertension Skin and subcutaneous tissue disorders : Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN) Vascular disorders : severe hypotension

adverse reactions table

<table frame="box" rules="all"> <tbody> <tr> <th rowspan="2"/> <th colspan="2">MDD</th> <th colspan="2">OCD</th> <th colspan="2">PD</th> <th colspan="2">SAD</th> <th colspan="2">GAD</th> <th colspan="2">PTSD</th> </tr> <tr align="center"> <td> <content styleCode="bold">PAXIL </content> </td> <td> <content styleCode="bold">Placebo </content> </td> <td> <content styleCode="bold">PAXIL </content> </td> <td> <content styleCode="bold">Placebo </content> </td> <td> <content styleCode="bold">PAXIL </content> </td> <td> <content styleCode="bold">Placebo </content> </td> <td> <content styleCode="bold">PAXIL </content> </td> <td> <content styleCode="bold">Placebo </content> </td> <td> <content styleCode="bold">PAXIL </content> </td> <td> <content styleCode="bold">Placebo </content> </td> <td> <content styleCode="bold">PAXIL </content> </td> <td> <content styleCode="bold">Placebo </content> </td> </tr> <tr align="center"> <td align="left" colspan="13"> <content styleCode="bold">CNS</content> <content styleCode="bold">Adverse Reactions</content> </td> </tr> <tr align="center"> <td align="left">Somnolence</td> <td>2.3%</td> <td>0.7%</td> <td>---</td> <td/> <td>1.9%</td> <td>0.3%</td> <td>3.4%</td> <td>0.3%</td> <td>2%</td> <td>0.2%</td> <td>2.8%</td> <td>0.6%</td> </tr> <tr align="center"> <td align="left">Insomnia</td> <td>---</td> <td>---</td> <td>1.7%</td> <td>0%</td> <td>1.3%</td> <td>0.3%</td> <td>3.1%</td> <td>0%</td> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Agitation</td> <td>1.1%</td> <td>0.5%</td> <td>---</td> <td/> <td/> <td/> <td/> <td/> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Tremor</td> <td>1.1%</td> <td>0.3%</td> <td>---</td> <td/> <td/> <td/> <td>1.7%</td> <td>0%</td> <td/> <td/> <td>1%</td> <td>0.2%</td> </tr> <tr align="center"> <td align="left">Anxiety</td> <td>---</td> <td>---</td> <td>---</td> <td/> <td/> <td/> <td>1.1%</td> <td>0%</td> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center" valign="bottom"> <td align="left">Dizziness</td> <td>---</td> <td>---</td> <td>1.5%</td> <td>0%</td> <td/> <td/> <td>1.9%</td> <td>0%</td> <td>1%</td> <td>0.2%</td> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left" colspan="13"> <content styleCode="bold">Gastrointestinal</content> <content styleCode="bold">Adverse Reactions</content> </td> </tr> <tr align="center"> <td align="left">Constipation</td> <td>---</td> <td/> <td>1.1%</td> <td>0%</td> <td/> <td/> <td/> <td/> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Nausea</td> <td>3.2%</td> <td>1.1%</td> <td>1.9%</td> <td>0%</td> <td>3.2%</td> <td>1.2%</td> <td>4%</td> <td>0.3%</td> <td>2%</td> <td>0.2%</td> <td>2.2%</td> <td>0.6%</td> </tr> <tr align="center"> <td align="left">Diarrhea</td> <td>1%</td> <td>0.3%</td> <td>---</td> <td/> <td/> <td/> <td/> <td/> <td/> <td/> <td/> <td/> </tr> <tr align="center"> <td align="left">Dry mouth</td> <td>1%</td> <td>0.3%</td> <td>---</td> <td/> <td/> <td/> <td/> <td/> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Vomiting</td> <td>1%</td> <td>0.3%</td> <td>---</td> <td/> <td/> <td/> <td>1%</td> <td>0%</td> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Flatulence</td> <td/> <td/> <td/> <td/> <td/> <td/> <td>1%</td> <td>0.3%</td> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left" colspan="13"> <content styleCode="bold">Other</content> <content styleCode="bold">Adverse Reactions</content> </td> </tr> <tr align="center"> <td align="left">Asthenia</td> <td>1.6%</td> <td>0.4%</td> <td>1.9%</td> <td>0.4%</td> <td/> <td/> <td>2.5%</td> <td>0.6%</td> <td>1.8%</td> <td>0.2%</td> <td>1.6%</td> <td>0.2%</td> </tr> <tr align="center"> <td align="left">Abnormal Ejaculation<sup>a</sup> </td> <td>1.6%</td> <td>0%</td> <td>2.1%</td> <td>0%</td> <td/> <td/> <td>4.9%</td> <td>0.6%</td> <td>2.5%</td> <td>0.5%</td> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Sweating</td> <td>1%</td> <td>0.3%</td> <td>---</td> <td/> <td/> <td/> <td>1.1%</td> <td>0%</td> <td>1.1%</td> <td>0.2%</td> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left">Impotence<sup>a</sup> </td> <td>---</td> <td/> <td>1.5%</td> <td>0%</td> <td/> <td/> <td/> <td/> <td/> <td/> <td>---</td> <td>---</td> </tr> <tr align="center"> <td align="left" colspan="7">Libido Decreased</td> <td>1%</td> <td colspan="1">0%</td> <td colspan="2"/> <td>---</td> <td>---</td> </tr> </tbody> </table>

adverse reactions table

<table frame="border" rules="all" width="55%"> <tbody> <tr> <th align="left"> <content styleCode="bold"/> </th> <th> <content styleCode="bold">PAXIL</content> <content styleCode="bold"> (n</content> <content styleCode="bold"> = 421)</content> <content styleCode="bold"> </content> </th> <th> <content styleCode="bold">Placebo</content> <content styleCode="bold"> (n</content> <content styleCode="bold"> = 421)</content> <content styleCode="bold"> </content> </th> </tr> <tr> <td>Nausea</td> <td align="center">26%</td> <td align="center">9%</td> </tr> <tr> <td>Somnolence</td> <td align="center">23%</td> <td align="center">9%</td> </tr> <tr> <td>Dry Mouth</td> <td align="center">18%</td> <td align="center">12%</td> </tr> <tr> <td>Headache</td> <td align="center">18%</td> <td align="center">17%</td> </tr> <tr> <td>Asthenia</td> <td align="center">15%</td> <td align="center">6%</td> </tr> <tr> <td>Constipation</td> <td align="center">14%</td> <td align="center">9%</td> </tr> <tr> <td>Ejaculatory Disyurbance<sup>a</sup> </td> <td align="center">13%</td> <td align="center">0%</td> </tr> <tr> <td>Dizziness</td> <td align="center">13%</td> <td align="center">6%</td> </tr> <tr> <td>Insomnia</td> <td align="center">13%</td> <td align="center">6%</td> </tr> <tr> <td>Diarrhea</td> <td align="center">12%</td> <td align="center">8%</td> </tr> <tr> <td>Sweating</td> <td align="center">11%</td> <td align="center">2%</td> </tr> <tr> <td>Other Male Genital Disorders<sup>b</sup> </td> <td align="center">10%</td> <td align="center">0%</td> </tr> <tr> <td>Tremor</td> <td align="center">8%</td> <td align="center">2%</td> </tr> <tr> <td>Decreased Appetite</td> <td align="center">6%</td> <td align="center">2%</td> </tr> <tr> <td>Nervousness</td> <td align="center">5%</td> <td align="center">3%</td> </tr> <tr> <td>Anxiety</td> <td align="center">5%</td> <td align="center">3%</td> </tr> <tr> <td>Yawn</td> <td align="center">4%</td> <td align="center">0%</td> </tr> <tr> <td>Blurred Vision</td> <td align="center">4%</td> <td align="center">1%</td> </tr> <tr> <td>Flatulence</td> <td align="center">4%</td> <td align="center">2%</td> </tr> <tr> <td>Paresthesia</td> <td align="center">4%</td> <td align="center">2%</td> </tr> <tr> <td>Palpitation</td> <td align="center">3%</td> <td align="center">1%</td> </tr> <tr> <td>Vasodilation</td> <td align="center">3%</td> <td align="center">1%</td> </tr> <tr> <td>Libido Decreased</td> <td align="center">3%</td> <td align="center">0%</td> </tr> <tr> <td>Urination Disorder<sup>d</sup> </td> <td align="center">3%</td> <td align="center">0%</td> </tr> <tr> <td>Urinary Frequency</td> <td align="center">3%</td> <td align="center">1%</td> </tr> <tr> <td>Taste Perversion</td> <td align="center">2%</td> <td align="center">0%</td> </tr> <tr> <td>Female Genital Disorders<sup>d</sup> </td> <td align="center">2%</td> <td align="center">0%</td> </tr> <tr> <td>Oropharynx Disorder<sup>e</sup> </td> <td align="center">2%</td> <td align="center">0%</td> </tr> <tr> <td>Myopathy </td> <td align="center">2%</td> <td align="center">1%</td> </tr> <tr> <td>Dyspepsia</td> <td align="center">2%</td> <td align="center">1%</td> </tr> <tr> <td>Rash</td> <td align="center">2%</td> <td align="center">1%</td> </tr> <tr> <td>Drugged Feeling</td> <td align="center">2%</td> <td align="center">1%</td> </tr> <tr> <td>Myalgia</td> <td align="center">2%</td> <td align="center">1%</td> </tr> <tr> <td>Confusion</td> <td align="center">1%</td> <td align="center">0%</td> </tr> <tr> <td>Myasthenia</td> <td align="center">1%</td> <td align="center">0%</td> </tr> </tbody> </table>

adverse reactions table

<table border="all" frame="border" rules="all" width="65%"> <tbody> <tr> <th rowspan="2"/> <th rowspan="2">Placebo (n = 51)</th> <th colspan="4">PAXIL</th> </tr> <tr> <th> <content styleCode="bold">10 mg/day</content> <content styleCode="bold">(n=102)</content> </th> <th> <content styleCode="bold">20 mg/day</content> <content styleCode="bold">(n=104)</content> </th> <th> <content styleCode="bold">30 mg/day</content> <content styleCode="bold">(n=101)</content> </th> <th> <content styleCode="bold">40 mg/day</content> <content styleCode="bold">(n=102)</content> </th> </tr> <tr> <td>Nausea</td> <td align="center">14%</td> <td align="center">15%</td> <td align="center">27%</td> <td align="center">35%</td> <td align="center">36%</td> </tr> <tr align="center"> <td align="left" scope="row">Somnolence</td> <td align="center">8%</td> <td align="center">13%</td> <td align="center">18%</td> <td align="center">21%</td> <td>22%</td> </tr> <tr align="center"> <td align="left">Dry Mouth</td> <td>2%</td> <td>11%</td> <td>18%</td> <td>16%</td> <td>21%</td> </tr> <tr align="center"> <td align="left">Diarrhea</td> <td>8%</td> <td>10%</td> <td>19%</td> <td>8%</td> <td>15%</td> </tr> <tr align="center"> <td align="left">Tremor</td> <td>8%</td> <td>0%</td> <td>8%</td> <td>8%</td> <td>15%</td> </tr> <tr align="center"> <td align="left">Asthenia</td> <td>0%</td> <td>3%</td> <td>11%</td> <td>14%</td> <td>13%</td> </tr> <tr align="center"> <td align="left">Abnormal Ejaculation</td> <td>0%</td> <td>6%</td> <td>7%</td> <td>11%</td> <td>13%</td> </tr> <tr align="center"> <td align="left">Constipation</td> <td>6%</td> <td>5%</td> <td>8%</td> <td>10%</td> <td>13%</td> </tr> <tr align="center"> <td align="left">Dizziness</td> <td>4%</td> <td>7%</td> <td>8%</td> <td>9%</td> <td>13%</td> </tr> <tr align="center"> <td align="left">Sweating</td> <td>2%</td> <td>1%</td> <td>7%</td> <td>9%</td> <td>12%</td> </tr> <tr align="center"> <td align="left">Blurred Vision</td> <td>2%</td> <td>3%</td> <td>3%</td> <td>2%</td> <td>8%</td> </tr> <tr align="center"> <td align="left">Anxiety</td> <td>0%</td> <td>2%</td> <td>6%</td> <td>6%</td> <td>6%</td> </tr> <tr align="center"> <td align="left">Paresthesia</td> <td>0%</td> <td>3%</td> <td>1%</td> <td>5%</td> <td>6%</td> </tr> <tr align="center"> <td align="left">Decreased Appetite</td> <td>2%</td> <td>2%</td> <td>6%</td> <td>4%</td> <td>5%</td> </tr> <tr align="center"> <td align="left">Male Genital Disorders</td> <td>0%</td> <td>4%</td> <td>9%</td> <td>6%</td> <td>4%</td> </tr> <tr align="center"> <td align="left">Nervousness</td> <td>0%</td> <td>6%</td> <td>6%</td> <td>4%</td> <td>3%</td> </tr> <tr align="center"> <td align="left">Impotence</td> <td>0%</td> <td>2%</td> <td>4%</td> <td>6%</td> <td>2%</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.